Consequently, targeting a single activating EGFR-mutation will eventually result in treatment failure, because pre-existing or swiftly induced resistant cells will, by variable mechanisms and at different times and tumor locations, expand and prevail. This evidence concerns the gene EGFR and neoplasm.